Showing 4011-4020 of 4062 results for "".
- Iridex Reaches Milestone of 1000th Cyclo G6 System Shippedhttps://modernod.com/news/iridex-reaches-milestone-of-1000th-cyclo-g6-system-shipped/2480033/Iridex announced that in the second quarter of 2018 it shipped the 1,000th unit of its »Cyclo G6 Laser System, which utilizes the company’s propri
- Takeda Receives Clearance from the FTC for the Proposed Acquisition of Shirehttps://modernod.com/news/takeda-receives-clearance-from-the-ftc-for-the-proposed-acquisition-of-shire/2480035/Takeda Pharmaceutical announced that it has received unconditional clearance from the United States Federal Trade Commission (FTC) for the proposed acquisition of Shire announced on May 8, 2018. Takeda’s proposed acquisition of Shire is valued at around 46 billion pounds ($60.9 billion).
- Bausch + Lomb Announces FDA Filing Acceptance for Loteprednol Etabonate Ophthalmic Gelhttps://modernod.com/news/bausch-lomb-announces-fda-filing-acceptance-for-loteprednol-etabonate-ophthalmic-gel/2480037/Bausch + Lomb announced that the FDA has accepted the new drug application (NDA) for its sub-micron loteprednol etabonate ophthalmic gel 0.38%. The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2019. If approved, the product would be the lowest concentrated lote
- Eyenovia Appoints Michael Rowe as Vice President of Marketinghttps://modernod.com/news/eyenovia-appoints-michael-rowe-as-vice-president-of-marketing/2480038/Eyenovia announced the appointment of Michael Rowe as Vice President of Marketing. Mr. Rowe is a veteran marketing professional with more than 20 years of experience in commercializing products and devices in the United States and globally across the healthcare industry.
- MPOD Measurement Earns American Medical Association CPT III Codehttps://modernod.com/news/mpod-measurement-earns-american-medical-association-cpt-iii-code/2480039/EyePromise announced that on July 1, 2018, macular pigment optical density (MPOD) measurement by heterochromatic flicker photometry has earned a Category III CPT Code from the American Medical Association. While this code does not receive paid reimbursement, Category III CPT Codes are used for da
- Katena Products Announces the Acquisition of Blink Medicalhttps://modernod.com/news/katena-products-announces-the-acquisition-of-blink-medical/2480044/Katena Products announced the purchase of Blink Medical, a UK-based provider of primarily single use ophthalmic instruments. Terms of the deal were not announced. Founded in 2004, Blink Medical currently distributes its products within Europe and the Middle East.
- ThromboGenics Plans Name Change to “Oxurion”https://modernod.com/news/thrombogenics-plans-name-change-to-oxurion/2480064/ThromboGenics announced its intention to change its name to “Oxurion” and the company’s stock ticker symbol from ‘THR” to “OXUR.” The company issued a convening notice seeking the approval of ThromboGenics’ shareholders for the name change at an Extraordinary Genera
- Silicon Valley Eye Doctor Named Optometrist of the Year By American Optometric Associationhttps://modernod.com/news/silicon-valley-eye-doctor-named-optometrist-of-the-year-by-american-optometric-association/2480071/The California Optometric Association (COA) announced that David M. Redman, OD, has been named the “Optometrist of the Year” for 2017 by the American Optometric Association (AOA). Dr. Redman is a practicing optometrist and partner in Precision Eyecare Centers in San Jose and Mountain View. Dr. Re
- RightEye Unveils EyeQ Trainer Personalized Computer-Based Vision Training Systemhttps://modernod.com/news/righteye-unveils-eyeq-trainer-personalized-computer-based-vision-training-system/2480076/RightEye unveiled its new EyeQ Trainer computer-based vision rehabilitation program at Optometry’s Meeting 2018 in Denver, Colorado (RightEye booth #611). EyeQ Trainer gives optometrists a tool their
- Foundation Fighting Blindness Launches the Stargardt Disease Natural History Studyhttps://modernod.com/news/foundation-fighting-blindness-launches-the-stargardt-disease-natural-history-study/2480086/More than 60 leading retinal disease clinical researchers from around the world gathered in Baltimore on June 11, 2018 to discuss findings from ProgStar, the Stargardt disease natural history study launched by the Foundation Fighting